← Back to Search

Nonsteroidal Anti-inflammatory Drug

Naproxen tablet for Pharmacogenetics

Phase 4
Waitlist Available
Led By Kenneth E. Thummel, PhD
Research Sponsored by University of Washington
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24-hours
Awards & highlights

Study Summary

This trial will study the effects of a gene polymorphism on the function of an enzyme involved in metabolizing a medication.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24-hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24-hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
6-O-desmethyl naproxen/naproxen ratio

Side effects data

From 2014 Phase 1 trial • 24 Patients • NCT02632812
17%
Heartburn
8%
Abdominal pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Rebamipide 200 mg
Placebo

Trial Design

1Treatment groups
Experimental Treatment
Group I: Naproxen TabletExperimental Treatment1 Intervention
Subjects will received a single 220-mg dose of naproxen sodium (Aleve) by mouth.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Naproxen
FDA approved

Find a Location

Who is running the clinical trial?

University of WashingtonLead Sponsor
1,741 Previous Clinical Trials
1,847,736 Total Patients Enrolled
Oregon Health and Science UniversityOTHER
974 Previous Clinical Trials
7,385,882 Total Patients Enrolled
National Institute of General Medical Sciences (NIGMS)NIH
269 Previous Clinical Trials
247,082 Total Patients Enrolled
1 Trials studying Pharmacogenetics
190 Patients Enrolled for Pharmacogenetics

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Naproxen Pharmacogenetic Study (Project 1, Aim 2)
Kenneth Thummel 2016. "Naproxen Pharmacogenetic Study (Project 1, Aim 2)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04449471.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top